The causative relation of human papilloma virus with the cervical cancer and its precursors is well known. Effective vaccines, based on virus like particles (L1 and L2) against these viruses have been developed. They ensure primary prophylaxis through the production of neutralized antibodies. In this connection, the present review summarized the existing world experience of the clinical application of the developed bi- and quadrivalent HPV vaccines, according to beginning of their occurrence.